UA111599C2 - Композиція каспофунгіну - Google Patents
Композиція каспофунгінуInfo
- Publication number
- UA111599C2 UA111599C2 UAA201304481A UAA201304481A UA111599C2 UA 111599 C2 UA111599 C2 UA 111599C2 UA A201304481 A UAA201304481 A UA A201304481A UA A201304481 A UAA201304481 A UA A201304481A UA 111599 C2 UA111599 C2 UA 111599C2
- Authority
- UA
- Ukraine
- Prior art keywords
- composition
- preparation
- lyophilized
- pharmaceutically acceptable
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Винахід належить до композиції, способу її одержання та застосування, що містить фармацевтично ефективну кількість ацетатної солі каспофунгіну, фармацевтично прийнятну кількість одного або більше ніж одного фармацевтично прийнятного ексципієнта, ефективного для утворення ліофілізованої таблетки та фармацевтично ефективну кількість буферного агента, що є сукцинатом. Також винахід належить до ліофілізованого препарату парентерального введення для лікування або попередження грибкової інфекції, що складається з заявленої композиції та набору, що містить вказаний ліофілізований препарат.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38433310P | 2010-09-20 | 2010-09-20 | |
PCT/EP2011/066202 WO2012038371A1 (en) | 2010-09-20 | 2011-09-19 | Caspofungin composition |
Publications (1)
Publication Number | Publication Date |
---|---|
UA111599C2 true UA111599C2 (uk) | 2016-05-25 |
Family
ID=44677877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201304481A UA111599C2 (uk) | 2010-09-20 | 2011-09-19 | Композиція каспофунгіну |
Country Status (20)
Country | Link |
---|---|
US (2) | US20120101030A1 (uk) |
EP (1) | EP2618814B1 (uk) |
JP (1) | JP5914486B2 (uk) |
KR (1) | KR20130136466A (uk) |
CN (1) | CN103118663A (uk) |
AU (1) | AU2011304408B2 (uk) |
CA (1) | CA2810112A1 (uk) |
DK (1) | DK2618814T3 (uk) |
ES (1) | ES2593727T3 (uk) |
HR (1) | HRP20161236T1 (uk) |
HU (1) | HUE030464T2 (uk) |
IL (1) | IL225339A0 (uk) |
MX (1) | MX2013003045A (uk) |
PL (1) | PL2618814T3 (uk) |
PT (1) | PT2618814T (uk) |
RS (1) | RS55216B1 (uk) |
RU (1) | RU2013114993A (uk) |
UA (1) | UA111599C2 (uk) |
WO (1) | WO2012038371A1 (uk) |
ZA (1) | ZA201302113B (uk) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103212058A (zh) * | 2012-01-18 | 2013-07-24 | 江苏恒瑞医药股份有限公司 | 含有抗真菌药物和乳酸盐缓冲剂的组合物 |
CN103212059A (zh) * | 2012-01-18 | 2013-07-24 | 江苏恒瑞医药股份有限公司 | 含有抗真菌药物和乳酸盐缓冲液的组合物 |
SI2922530T1 (sl) * | 2012-11-20 | 2017-04-26 | Fresenius Kabi Usa, Llc | Formulacije kaspofugin acetata |
CN103142997A (zh) * | 2013-03-13 | 2013-06-12 | 浙江海正药业股份有限公司 | 含有抗真菌剂和琥珀酸盐缓冲液的药物组合物 |
KR20140123782A (ko) * | 2013-04-15 | 2014-10-23 | 에스케이케미칼주식회사 | 카스포펀진 및 완충제를 포함하는 안정성이 개선된 약학적 조성물 |
CN104116716A (zh) * | 2013-04-25 | 2014-10-29 | 四川海思科制药有限公司 | 一种含卡泊芬净的冻干粉针剂药物组合物 |
ES2853349T3 (es) * | 2013-10-07 | 2021-09-15 | Galenicum Health S L U | Formulaciones farmacéuticas estables |
GR1008818B (el) * | 2015-05-22 | 2016-08-01 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου |
CN108760937B (zh) * | 2018-07-27 | 2020-12-29 | 杭州华东医药集团新药研究院有限公司 | 醋酸卡泊芬净中残留乙二胺的测定及其应用 |
CN109758426B (zh) * | 2019-01-24 | 2021-04-27 | 四川制药制剂有限公司 | 一种注射用醋酸卡泊芬净药物组合物及其制备方法 |
CN110859950B (zh) * | 2019-11-25 | 2021-08-10 | 武汉大学 | 一种用于白念珠菌棘白菌素类药物耐药菌的药物组合物及其应用 |
EP4364566A1 (en) * | 2022-11-04 | 2024-05-08 | B. Braun Melsungen AG | Anti-fungal composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7673991A (en) * | 1990-03-30 | 1991-10-30 | Smithkline Beecham Corporation | Method for treating fungal infection |
US5378894A (en) | 1991-12-11 | 1995-01-03 | Kabushiki Kaisha Toshiba | X-ray detector including scintillator channel separator capable of improving sensitivity of X-ray detector |
US5378804A (en) | 1993-03-16 | 1995-01-03 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
US5952300A (en) | 1996-04-19 | 1999-09-14 | Merck & Co., Inc. | Antifungal compositions |
US20080046580A1 (en) | 2006-06-29 | 2008-02-21 | Nokia Corporation | Account creation system and call processing system |
BRPI0715113A2 (pt) * | 2006-07-26 | 2013-06-04 | Sandoz Ag Sandoz Sa Sandoz Ltd | formulaÇço de caspofungina |
CN101516387B (zh) * | 2006-07-26 | 2014-06-04 | 桑多斯股份公司 | 卡泊芬净制剂 |
AU2008269140A1 (en) | 2007-06-26 | 2008-12-31 | Merck Sharp & Dohme Corp. | Lyophilized anti-fungal composition |
EP2285236A1 (en) * | 2008-05-30 | 2011-02-23 | DSM IP Assets B.V. | Use of succinic acid |
EP2183271A1 (en) | 2008-06-25 | 2010-05-12 | TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Caspofungin free of caspofungin impurity a |
-
2011
- 2011-09-19 MX MX2013003045A patent/MX2013003045A/es active IP Right Grant
- 2011-09-19 RU RU2013114993/15A patent/RU2013114993A/ru not_active Application Discontinuation
- 2011-09-19 KR KR1020137010070A patent/KR20130136466A/ko not_active Application Discontinuation
- 2011-09-19 UA UAA201304481A patent/UA111599C2/uk unknown
- 2011-09-19 RS RS20160810A patent/RS55216B1/sr unknown
- 2011-09-19 WO PCT/EP2011/066202 patent/WO2012038371A1/en active Application Filing
- 2011-09-19 ES ES11761049.3T patent/ES2593727T3/es active Active
- 2011-09-19 PT PT117610493T patent/PT2618814T/pt unknown
- 2011-09-19 EP EP11761049.3A patent/EP2618814B1/en active Active
- 2011-09-19 HU HUE11761049A patent/HUE030464T2/en unknown
- 2011-09-19 CA CA2810112A patent/CA2810112A1/en not_active Abandoned
- 2011-09-19 AU AU2011304408A patent/AU2011304408B2/en not_active Ceased
- 2011-09-19 DK DK11761049.3T patent/DK2618814T3/en active
- 2011-09-19 JP JP2013528699A patent/JP5914486B2/ja not_active Expired - Fee Related
- 2011-09-19 CN CN2011800451119A patent/CN103118663A/zh active Pending
- 2011-09-19 PL PL11761049T patent/PL2618814T3/pl unknown
- 2011-09-20 US US13/237,193 patent/US20120101030A1/en not_active Abandoned
-
2013
- 2013-03-19 IL IL225339A patent/IL225339A0/en unknown
- 2013-03-20 ZA ZA2013/02113A patent/ZA201302113B/en unknown
-
2014
- 2014-11-19 US US14/547,742 patent/US9393307B2/en active Active
-
2016
- 2016-09-28 HR HRP20161236TT patent/HRP20161236T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CN103118663A (zh) | 2013-05-22 |
US9393307B2 (en) | 2016-07-19 |
US20150072923A1 (en) | 2015-03-12 |
WO2012038371A1 (en) | 2012-03-29 |
AU2011304408B2 (en) | 2015-01-15 |
DK2618814T3 (en) | 2016-10-10 |
EP2618814B1 (en) | 2016-07-27 |
RU2013114993A (ru) | 2014-10-27 |
PT2618814T (pt) | 2016-10-06 |
JP5914486B2 (ja) | 2016-05-11 |
PL2618814T3 (pl) | 2017-01-31 |
HUE030464T2 (en) | 2017-05-29 |
KR20130136466A (ko) | 2013-12-12 |
AU2011304408A1 (en) | 2013-03-28 |
ES2593727T3 (es) | 2016-12-12 |
HRP20161236T1 (hr) | 2016-11-18 |
MX2013003045A (es) | 2013-06-24 |
US20120101030A1 (en) | 2012-04-26 |
IL225339A0 (en) | 2013-06-27 |
JP2013537212A (ja) | 2013-09-30 |
RS55216B1 (sr) | 2017-02-28 |
CA2810112A1 (en) | 2012-03-29 |
EP2618814A1 (en) | 2013-07-31 |
ZA201302113B (en) | 2014-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA111599C2 (uk) | Композиція каспофунгіну | |
WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
IL223783B (en) | Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
NZ703064A (en) | Inhibitors of hepatitis c virus | |
MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
CL2012001080A1 (es) | Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida. | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
MX348823B (es) | Formulaciones estables de linaclotida. | |
WO2011086093A3 (en) | Pharmaceutical compositions for oral administration of insulin peptides | |
NZ708016A (en) | Lyophilized preparations of melphalan flufenamide | |
IN2013MU03583A (uk) | ||
MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
MX350746B (es) | Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral. | |
MX2013004190A (es) | Composiciones y metodos para el tratamiento de la hipertension pulmonar. | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
NZ600695A (en) | Combination composition, comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency | |
MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
MY193996A (en) | Tripeptide compound, preparation method therefor, and application thereof | |
BR112015027436A2 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
WO2013096335A8 (en) | ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT | |
EP2611799A4 (en) | PHARMACEUTICAL COMPOSITIONS OF LINEZOLID | |
MX370957B (es) | Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevención de la dermatitis atópica. |